Druggability & Clinical Context
Druggability
Low
Score: 0.41
Druggability Analysis
Structural Tractability0.85
Key Metrics
PDB Structures:
18
Known Drugs:
1
Approved:
0
In Clinical Trials:
0
Drug Pipeline (1 compounds)
1 Preclinical
Therapeutic Areas:Alzheimer's disease Parkinson's disease Huntington's disease Ischemic stroke/reperfusion injury Acute myocardial infarction Heart failure Neurodegeneration Neurodegenerative disorders
Druggability Rationale: Despite the compelling mechanistic rationale for MCU inhibition in neurodegeneration, the target currently presents low druggability due to limited specific small molecule modulators and structural complexity of the mitochondrial calcium uniporter complex. While research tools like Ruthenium Red demonstrate proof-of-concept for channel blockade, translating these findings into clinically viable neurotherapeutics remains challenging, necessitating more sophisticated structural insights and rational drug design strategies to overcome current limitations in selective targeting and pharmacological intervention.
Mechanism: MCU inhibitors block the mitochondrial calcium uniporter channel, reducing excessive calcium accumulation in mitochondria that leads to oxidative stress, energy depletion, and cell death. This mechanism may protect against ischemic injury, neurodegeneration, and heart failure by preserving mitochondrial function and preventing apoptosis in calcium-sensitive tissues.
Drug Pipeline (1 compounds)
1 Preclinical
Known Drugs:Ruthenium Red (research_tool) — mitochondrial calcium transport inhibition
Structural Data:PDB (18) ✓AlphaFold ✓Cryo-EM ✓
Binding Pocket Analysis:MCU possesses a calcium-selective ion-conducting pore formed by conserved aspartate and glutamate residues within the transmembrane domain, with allosteric regulatory sites for MICU and EMRE binding partners. High-resolution structures reveal a narrow selectivity filter and a potential small-molecule binding cavity proximal to the pore entrance, suitable for competitive or non-competitive inhibitor design.
Selectivity & Safety Considerations
MCU selectivity must be balanced against MICU (mitochondrial calcium uniporter channel) and other calcium channels to avoid broad off-target effects on cellular calcium homeostasis. The channel's tissue-specific expression in high-energy-demand tissues (neurons, cardiomyocytes) provides some therapeutic window, but excessive inhibition risks energy depletion and paradoxical cell death in these same tissues.
Clinical Trials (10)
Relevant trials from ClinicalTrials.gov
By Phase
NA: 2 · Unknown: 8
Unknown
NCT01343901
n=210
Colorectal Cancer
Interventions: Bevacizumab
Sponsor: Hoffmann-La Roche
Unknown
NCT03621839
n=50000
Alzheimer Disease, Dementia, Neurodegenerative Diseases
Sponsor: Central Hospital, Nancy, France
NA
NCT03002142
n=9
Alzheimer's Disease, Hearing Loss
Interventions: Hearing aids, Placebo
Sponsor: University Hospital, Tours
Unknown
NCT00695656
n=2853
Hypertension
Sponsor: AstraZeneca
NA
NCT04150198
n=45
Alzheimer Disease, Early Onset, Posterior Cortical Atrophy
Interventions: TEP/IRM
Sponsor: Institut National de la Santé Et de la Recherche Médicale, F
Unknown
NCT01211652
n=8186
Healthy
Sponsor: AstraZeneca
Unknown
NCT01308372
n=9246
Healthy
Sponsor: AstraZeneca
Unknown
NCT01574235
n=2114
Solid Tumors, Malignant Hemopathy, Chemotherapy-induced Febrile Neutropenia
Interventions: Nivestim®
Sponsor: Hospira, now a wholly owned subsidiary of Pfizer